The Drug Discovery Services Market is gaining importance as pharmaceutical companies seek cost-effective ways to accelerate early-stage research and strengthen development pipelines. Market Research Future estimates that the market will increase from USD 115.08 billion in 2025 to USD 216.04 billion by 2035 at a CAGR of 6.50%.

One of the major growth drivers is the rising cost and complexity of drug development. Pharmaceutical and biotechnology companies can outsource specialized research to CROs instead of maintaining every capability internally. This approach can provide access to advanced laboratories, scientific expertise, screening libraries, computational platforms, and specialized assays.

The adoption of AI is creating another significant opportunity. Generative AI, machine learning, and computational chemistry are increasingly being applied to target identification and molecular design. AI and machine-learning technologies are forecast to be among the fastest-growing technology segments, with a projected 10.30% CAGR through 2035.

The growing biologics pipeline is also creating demand for specialized discovery services. Antibody-drug conjugates, bispecific antibodies, and other large-molecule therapies require advanced discovery, screening, and optimization capabilities.

Asia-Pacific presents substantial opportunities because China and India are expanding biotechnology infrastructure and CRO capacity. The region is forecast to grow at a 12.10% CAGR through 2035.

As pharmaceutical pipelines become more complex, integrated discovery partnerships are expected to become increasingly valuable across the global industry.